Table 2.
Per-country analysis of DCR/SIF characteristics (country vs. other; chi2 test, if not stated otherwise)
| Netherlands n = 8 |
Switzerland n = 7 |
Germany n = 17 |
Spain n = 9 |
Remaining countries n = 8 |
Total n = 49 |
|
|---|---|---|---|---|---|---|
| proportion (%) | proportion (%) | proportion (%) | proportion (%) | proportion (%) | proportion (%) | |
| Operational | ||||||
| Operated by the government | 4/8(50.0) | 3/6(40.0) | 2/14(14.3*) | 4/9(44.4) | 5/8(62.5) | 18/45(40.0) |
| Funding from local government | 8/8(100.0*) | 3/5(60.0) | 11/15(73.3) | 6/9(66.7) | 4/8(50.0) | 32/45(71.1) |
| Co-located with another program | 5/8(62.5) | 4/6(66.7) | 10/15(66.7) | 3/9(33.3) | 4/8(50.0) | 26/46(56.5) |
| Stand-alone facility with other services nearby | 0/8(0.0*) | 2/6(33.3) | 3/15(20.0) | 4/9(44.4) | 5/8(62.5*) | 14/46(30.4) |
| Staff-Related | ||||||
| Employing a nurse | 4/8(50.0*) | 6/6(100.0) | 11/15(73.3) | 8/9(88.9) | 8/8(100.0) | 37/46(80.4) |
| Employing a medical doctor | 3/8(37.5) | 0/6(0.0*) | 7/15(46.7) | 4/9(44.4) | 6/8(75.0*) | 20/46(43.5) |
| Employing peer workers | 3/8(37.5) | 2/6(33.3) | 1/15(6.7) | 1/9(11.1) | 3/8(37.5) | 10/46(21.7) |
| Number of paid staff on average day - n (mean country / other - t-test) | 6(3/8*) | 6(6/8) | 13(8/7) | 9(7/7) | 8(11/7*) | 42(7) |
| Client-Related | ||||||
| Number of attendees per day - n (mean country / other - t-test) | 7(16/130*) | 5(158/100) | 12(106/108) | 8(109/107) | 4(206/95*) | 36(108) |
| % of clients tested for HCV - n (mean country / other - t-test) | 5(59/72) | 5(78/69) | 14(77/67) | 9(77/69) | 8(54/75) | 41(71) |
| % of clients estimated as HCV positive - n (mean country / other - t-test) | 5(33/61**) | 5(51/59) | 15(57/58) | 8(69/55*) | 8(67/55) | 41(58) |
| Service-Related | ||||||
| Naloxone onsite | 1/8(12.5) | 1/6(16.7) | 4/15(26.7) | 8/9(88.9***) | 3/8(37.5) | 17/46(37.0) |
| HIV counselling onsite | 1/8(12.5***) | 3/6(50.0) | 14/15(93.3*) | 8/9(88.9) | 6/8(75.0) | 32/46(69.6) |
| HIV testing onsite | 0/8(0.0***) | 2/6(33.3) | 9/15(60.0) | 8/9(88.9*) | 6/8(75.0) | 25/46(54.4) |
| OST onsite | 2/8(25.0) | 0/6(0.0) | 5/15(33.3) | 3/9(33.3) | 1/8(12.5) | 11/46(23.9) |
| HBV vaccination onsite | 1/8(12.5) | 1/6(16.7) | 7/15(46.7) | 6/9(66.7) | 4/8(50.0) | 19/46(41.3) |
| Number of spaces for drug use - n (mean country / other - t-test) | 7(10/12) | 5(26/10***) | 15(11/12) | 8(5/13*) | 6(13/12) | 41(12) |
| HCV-Related services | ||||||
| HCV testing onsite | 2/7(28.6*) | 4/7(57.1) | 12/17(70.6) | 8/9(88.9) | 6/8(75.0) | 32/48(66.7) |
| Liver monitoring or disease management onsite | 2/7(28.6) | 2/6(33.3) | 11/17(64.7) | 5/8(62.5) | 5/8(62.5) | 25/46(54.4) |
| HCV treatment onsite or plan to provide in the future | 1/7(14.3) | 0/6(0.0) | 5/17(29.4) | 1/9(11.1) | 3/8(37.5) | 10/47(21.3) |
*statistically significant difference (country group vs. all other countries) on p < 0.05 level; **statistically significant difference on p < 0.01 level; ***statistically significant difference on p = 0.00 level